glp 1 and ampk GLP-1 Receptor Agonist Non-Alcoholic Fatty Liver Disease plus AMPK Glucagon-Like Peptide 1 Analogs and

L., le Roux, C

doi: 10.3389/fphar.2026.1747267 Received 16 November 2025 Revised 17 January 2026 Accepted 20 January 2026 Published 02 February 2026 Volume 17 - 2026 Edited by Weishuo Fang, Chinese Academy of Medical Sciences and Peking Union Medical College, China Reviewed by Yan Guo, The Second Military Medical University, China Muhammad Mazhar, Postdoctoral Researcher at Shenzhen University, Shenzhen, China Updates Copyright 2026 Zhang, Chen, Yu, Feng, Sammad, Wang and Yin

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement multidisciplinary consensus statement

Diabetes Care 2003;26:1759-63.PubMed 156

Nat Med 31:951962 Zhao K, Shkolnik B, Lu J, Miller J, Schulsinger D (2023) MP10-05 lithoprotective effect of glp-1 agonists in diabetic stone formers

Typical weight loss timeline: 1 month: reduced hunger 2 to 3 months: steady weight loss 3 to 6 months: visible body changes 6 to 12 months: significant fat reduction Results improve when combined with hydration, nutrition, and wellness support such as IV therapy